Lupin launches Mycophenolate Mofetil Capsules

04 Oct 2019 Evaluate

Lupin has launched Mycophenolate Mofetil Capsules USP, 250 mg. The company’s alliance partner Concord Biotech (Concord) had received an approval from the United States Food and Drug Administration (USFDA) earlier.

Mycophenolate Mofetil Capsules USP, 250 mg, is the generic version of Roche’s CellCept. Mycophenolate Mofetil Capsules are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants. Mycophenolate Mofetil Capsules USP, 250 mg, had annual sales of approximately $53 million in the US (IQVIA MAT August 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2055.05 3.00 (0.15%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×